ReviewWorld journal of orthopedics2014
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis.
Review in World journal of orthopedics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.Arthritis research & therapy · 2022Pooled it
- Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.Clinical rheumatology · 2019Pooled it
- A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2018Trial
- Recent trends in gene-targeted therapies and their influence on surgical decision-making in rheumatoid arthritis affecting the hands, feet, and ankles.Frontiers in medicine · 2025Review
- Drug Interaction Potential of Berberine Hydrochloride When Co-Administered with Tofacitinib and Filgotinib in Rats.Drug design, development and therapy · 2025Article
- Sarcopenia in Rheumatoid arthritis. A narrative review.Journal of frailty, sarcopenia and falls · 2023Review
- Development of Tofacitinib Loaded pH-Responsive Chitosan/Mucin Based Hydrogel Microparticles: In-Vitro Characterization and Toxicological Screening.Gels (Basel, Switzerland) · 2023Article
- Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways.Inflammopharmacology · 2021Review
- Protective effect of filgotinib in rat endotoxin-induced uveitis model.International ophthalmology · 2021Article
- Article
- JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data.Journal of inflammation research · 2020Review
- Tofacitinib in the treatment of active rheumatoid arthritis - single-centre experience.Reumatologia · 2019Article
- Tofacitinib Versus Non-Tumor Necrosis Factor Biologics for Patients With Active Rheumatoid Arthritis.Archives of rheumatology · 2018Article
- Interleukin-2 shapes the cytotoxic T cell proteome and immune environment-sensing programs.Science signaling · 2018Article
- Novel treatments for inflammatory bowel disease.The Korean journal of internal medicine · 2018Review
- A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer.Oncology letters · 2017Article
- A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects.BMJ open respiratory research · 2016Article
- Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.Rheumatology international · 2015Article
- Next-Generation Therapeutics for IBD.Current gastroenterology reports · 2015Review
- Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors.Frontiers in endocrinology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tofacitinib is the first in a new class of nonbiologic disease-modifying antirheumatic drugs (DMARDs), a targeted, synthetic DMARD, approved for the treatment of rheumatoid arthritis (RA) as monotherapy or in combination with methotrexate or other non-biologic DMARD. Tofacitinib, an orally administered Janus kinase (JAK) inhibitor, decreases T-cell activation, pro-inflammatory cytokine production, and cytokine signaling by inhibiting binding of type I cytokine receptors family and γ-chain cytokines to paired JAK1/JAK3 receptors. The net effect of tofacitinb's mechanism of action is decreased synovial inflammation and structural joint damage in RA patients. To date, six phase 3 trials have been conducted to evaluate the safety and efficacy of tofacitinib under the oral rheumatoid arthritis triaLs (ORAL) series. This review describes the pharmacology of the novel agent, tofacitinib, and details the safety and efficacy data of the ORAL trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.